Health System

In the first of its "FDA Drug Info Rounds," a new series of educational videos for pharmacists, FDA is tackling unapproved dispensing of colchicine.

Inhaled insulin may be making a comeback. That's the hope at MannKind, a California-based biopharmaceutical company developing a rapid-acting inhaled insulin known as Afrezza (insulin human rDNA origin).

A survey of new Rx, new generic, and new OTC products

The Drug Enforcement Administration has released its long-awaited interim final rule for electronic prescribing of controlled substances.

A ballot initiative moving toward approval in North Dakota could open the doors to chain pharmacy in the state.

Pharmacists now have another way to obtain continuing education credits for diabetes management.

The first non-drug treatment for severe asthma that is not well controlled by anti-inflammatory medicines won FDA approval April 27.

In the business world, it just seems like common sense that you dictate to your customers at your extreme peril. Even when you think God is on your side.

Bumps, bruises, and scrapes happen - especially during the summer months when knees and elbows are bare and so much time is spent outdoors. Many first-aid products can help.

The relationship between prescribing practitioners and nurses working in a long-term-care (LTC) facility is of significant concern to the LTC facility when controlled substances are needed.

Pharmacy directors who want to - or have to - operate 24/7 but don't have the staff to cover all 3 shifts have a new ally, the American Society of Health-System Pharmacists (ASHP).

The number of e-prescriptions filled last year soared 181% to 191 million, according to "Advancing Healthcare in America," a report issued by Surescripts in Alexandria, Va.

As Americans increasingly turn to vitamins and herbal supplements as alternatives to prescription drug use, medical professionals and government leaders worry that few realize the implications.

Patients treated over long periods with the diabetes drug metformin (Glucophage, Bristol-Myers Squibb) are at risk of developing vitamin-B12 deficiency, according to a study published in the British Medical Journal, Reuters has reported.

FDA is investigating hundreds of consumer complaints involving children's medicines recalled by Johnson & Johnson on April 30, according to a congressional memo, the Associated Press reported.

Pharmacists are the most trusted source for medical research information, according to a recent survey.

Walgreens and CVS Caremark have signed a multi-year contract to keep Walgreens in the Caremark pharmacy network, resolving recent issues between the drugstore chains, according to The Wall Street Journal.

The American Medical Association (AMA) has responded favorably to concerns expressed in April by the American Pharmacists Association and six other pharmacy associations.

Pharmacists Planning Service, Inc. is calling for papers for its 17th International Public Health & Pharmacy Issues Conference aboard Royal Caribbean's Adventure of the Seas.

Patients whose doctors over-prescribe antibiotics may develop drug resistance that can last up to a year, putting them and others at risk when more serious treatment is needed, according to a study published in May in the British Medical Journal.

The National Community Pharmacists Association (NCPA) will present the latest in pharmacy education, case studies, and real-world, business-oriented information for the independent community-pharmacy industry at its 112th Annual Convention and Trade Exposition taking place at the Pennsylvania Convention Center in Philadelphia Oct. 23 to 27.

FDA notified consumers and healthcare professionals that a product represented as "Generic Tamiflu" being sold on the Internet does not contain Tamiflu's active ingredient, oseltamivir, but cloxacillin, an ingredient in the same class of antibiotics as penicillin.

FDA last month launched "FDA Drug Info Rounds," a new educational video series for pharmacists.

FDA will provide access to its health information for consumers through a collaboration with Drugs.com, which will post the information at its website and on its mobile phone platform.

FDA announced that it will release risk summaries about medicines approved after September 2007 and post them quarterly to a publicly accessible website, Reuters reported.